ARCA biopharma Stock News

Clinical-stage biopharmaceutical firm ARCA Biopharma (NASDAQ: ABIO ) — which develops and commercializes cardiovascular disease therapies — saw its shares skyrocket during the midweek session. Ear

Arca Biopharma Inc (NASDAQ: ABIO) more than doubled on Wednesday after announcing a merger agreement with Oruka Therapeutics. Oruka CEO comments on Arca Biopharma stock deal The combined company follo

Activist is pushing ARCA biopharma to stop new developments and return cash to shareholders. Subsequently, management has started a strategic review.

ARCA biopharma Inc (NASDAQ: ABIO) announced results from the ASPEN-COVID-19 Phase 2 trial evaluating rNAPc2, a specific inhibitor of tissue factor, as a potential treatment for patients hospitalized

ARCA biopharma press release (ABIO): FY GAAP EPS of -$1.39.FY Cash and cash equivalents of $53.4M

ARCA biopharma Inc (ABIO) shares closed today at 1.5% above its 52 week low of $2.01, giving the company a market cap of $29M. The stock is currently down 5.1% year-to-date, down 51.7% over the past 12 months, and down 96.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 1.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -45.1% The company's stock price performance over the past 12 months lags the peer average by -1436.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

ARCA biopharma Inc (ABIO) shares closed today at 1.4% above its 52 week low of $2.17, giving the company a market cap of $32M. The stock is currently down 44.4% year-to-date, down 46.4% over the past 12 months, and down 95.7% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 17.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -268.9% The company's stock price performance over the past 12 months lags the peer average by -299.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

ARCA biopharma (NASDAQ: ABIO) is one of 38 publicly-traded companies in the Diagnostic substances industry, but how does it weigh in compared to its rivals? We will compare ARCA biopharma to related businesses based on the strength of its earnings, institutional ownership, dividends, profitability, risk, valuation and analyst recommendations. Risk & Volatility ARCA biopharma has []

ARCA biopharma (NASDAQ: ABIO) is one of 38 publicly-traded companies in the Diagnostic substances industry, but how does it weigh in compared to its rivals? We will compare ARCA biopharma to related companies based on the strength of its earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations. Risk and Volatility ARCA biopharma has []

ARCA biopharma (NASDAQ: ABIO) is one of 38 public companies in the Diagnostic substances industry, but how does it compare to its peers? We will compare ARCA biopharma to related businesses based on the strength of its risk, dividends, institutional ownership, valuation, profitability, analyst recommendations and earnings. Analyst Recommendations This is a breakdown of current []

ARCA biopharma (NASDAQ: ABIO) is one of 38 public companies in the Diagnostic substances industry, but how does it weigh in compared to its peers? We will compare ARCA biopharma to related companies based on the strength of its institutional ownership, dividends, profitability, valuation, analyst recommendations, earnings and risk. Valuation & Earnings This table compares []

ARCA biopharma is one of 38 public companies in the Diagnostic substances industry, but how does it contrast to its peers? We will compare ARCA biopharma to related

ARCA biopharma (NASDAQ: ABIO) is one of 38 public companies in the Diagnostic substances industry, but how does it contrast to its peers? We will compare ARCA biopharma to related businesses based on the strength of its institutional ownership, valuation, earnings, risk, profitability, dividends and analyst recommendations. Earnings and Valuation This table compares ARCA biopharma [] The post Reviewing ARCA biopharma (ABIO) & Its Peers appeared first on ETF Daily News .

ARCA biopharma (NASDAQ: ABIO) is one of 38 public companies in the Diagnostic substances industry, but how does it compare to its rivals? We will compare ARCA biopharma to similar businesses based on the strength of its dividends, earnings, profitability, valuation, risk, analyst recommendations and institutional ownership. Earnings and Valuation This table compares ARCA biopharma []

ARCA biopharma (NASDAQ: ABIO) is one of 38 public companies in the Diagnostic substances industry, but how does it weigh in compared to its peers? We will compare ARCA biopharma to related businesses based on the strength of its valuation, risk, analyst recommendations, dividends, institutional ownership, profitability and earnings. Volatility and Risk ARCA biopharma has []